New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis

Journal of Infection

Volumn 63, Issue 6, 2011, Pages 407-419

  Huttunen, Reetta ^a,b   Aittoniemi, Janne ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^c PIRKANMAA HOSPITAL DISTRICT   (Finland)

Author keywords

Antimicrobial resistance; Apoptosis; Blood culture; Immunosuppression; Molecular; Pathogenesis; Proinflammatory; Resistant; Sepsis; Therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD4 ANTIGEN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAPTOMYCIN; DROTRECOGIN; ENDOTOXIN; ERITORAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 7; LACTOFERRIN; LINEZOLID; MACROPHAGE MIGRATION INHIBITION FACTOR; METICILLIN; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; TOLL LIKE RECEPTOR; TRYPTOPHAN; TUMOR NECROSIS FACTOR; ZINC;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIGEN EXPRESSION; APOPTOSIS; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; DIAGNOSTIC PROCEDURE; DRUG CHOICE; DRUG MEGADOSE; DRUG TARGETING; EARLY INTERVENTION; ENZYME ACTIVATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY (TOPIC); NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PATIENT CARE; POLYMERASE CHAIN REACTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); ZINC DEFICIENCY;

ANTI-BACTERIAL AGENTS; BIOMEDICAL RESEARCH; HUMANS; IMMUNOLOGIC FACTORS; SEPSIS; TIME FACTORS;

EID: 82355173296     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.08.004     Document Type: Review

References (144)

1. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
2. Opal S.M., Esmon C.T. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003, 7:23-38.
3. Marshall J.C., Reinhart K. Biomarkers of sepsis. Crit Care Med 2009, 37:2290-2298.
4. Lamontagne F., Briel M., Duffett M., Fox-Robichaud A., Cook D.J., Guyatt G., et al. Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis. Crit Care Med 2010, 38:2401-2408.
5. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
6. Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6:813-822.
7. Hotchkiss R.S., Osmon S.B., Chang K.C., Wagner T.H., Coopersmith C.M., Karl I.E. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005, 174:5110-5118.
8. Kasten K.R., Tschop J., Adediran S.G., Hildeman D.A., Caldwell C.C. T cells are potent early mediators of the host response to sepsis. Shock 2010, 34:327-336.
9. Rubulotta F., Marshall J.C., Ramsay G., Nelson D., Levy M., Williams M. Predisposition, insult/infection, response, and organ dysfunction: A new model for staging severe sepsis. Crit Care Med 2009, 37:1329-1335.
10. Howell M.D., Talmor D., Schuetz P., Hunziker S., Jones A.E., Shapiro N.I. Proof of principle: the predisposition, infection, response, organ failure sepsis staging system. Crit Care Med 2011, 39:322-327.
11. Ferrer R., Artigas A., Suarez D., Palencia E., Levy M.M., Arenzana A., et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180:861-866.
12. Garnacho-Montero J., Aldabo-Pallas T., Garnacho-Montero C., Cayuela A., Jimenez R., Barroso S., et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006, 10:R111.
13. Samuelsen O., Toleman M.A., Sundsfjord A., Rydberg J., Leegaard T.M., Walder M., et al. Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob Agents Chemother 2010, 54:346-352.
14. Kanerva M., Salmenlinna S., Vuopio-Varkila J., Lehtinen P., Möttönen T., Virtanen M.J., et al. Community-associated methicillin-resistant Staphylococcus aureus isolated in Finland in 2004 to 2006. J Clin Microbiol 2009, 47:2655-2657.
15. Ammerlaan H., Seifert H., Harbarth S., Brun-Buisson C., Torres A., Antonelli M., et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 2009, 49:997-1005.
16. Zaragoza R., Artero A., Camarena J.J., Sancho S., Gonzalez R., Nogueira J.M. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9:412-418.
17. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
18. Kumar A., Ellis P., Arabi Y., Roberts D., Light B., Parrillo J.E., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237-1248.
19. Siddiqui S, Razzak J. Early versus late pre-intensive care unit admission broad spectrum antibiotics for severe sepsis in adults. Cochrane Database Syst Rev: CD007081.
20. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
21. Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004, 30:536-555.
22. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
23. Gaieski D.F., Mikkelsen M.E., Band R.A., Pines J.M., Massone R., Furia F.F., et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010, 38:1045-1053.
24. French G.L. What's new and not so new on the antimicrobial horizon?. Clin Microbiol Infect 2008, 14(Suppl. 6):19-29.
25. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36:53-59.
26. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60:913-920.
27. Kang C.I., Song J.H., Chung D.R., Peck K.R., Ko K.S., Yeom J.S., et al. Clinical impact of methicillin resistance on outcome of patients with Staphylococcus aureus infection: a stratified analysis according to underlying diseases and sites of infection in a large prospective cohort. J Infect 2010, 61:299-306.
28. Tängden T., Cars O., Melhus A., Löwdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010, 54:3564-3568.
29. Sands K.E., Bates D.W., Lanken P.N., Graman P.S., Hibberd P.L., Kahn K.L., et al. Epidemiology of sepsis syndrome in 8 academic medical centers. Jama 1997, 278:234-240.
30. Vincent J.L., Sakr Y., Sprung C.L., Ranieri V.M., Reinhart K., Gerlach H., et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
31. Paolucci M., Landini M.P., Sambri V. Conventional and molecular techniques for the early diagnosis of bacteraemia. Int J Antimicrob Agents 2010, 36(Suppl. 2):S6-S16.
32. Tissari P., Zumla A., Tarkka E., Mero S., Savolainen L., Vaara M., et al. Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet 2010, 375:224-230.
33. Leggieri N., Rida A., Francois P., Schrenzel J. Molecular diagnosis of bloodstream infections: planning to (physically) reach the bedside. Curr Opin Infect Dis 2010, 23:311-319.
34. Ecker D.J., Sampath R., Massire C., Blyn L.B., Hall T.A., Eshoo M.W., et al. Ibis T5000: a universal biosensor approach for microbiology. Nat Rev Microbiol 2008, 6:553-558.
35. Emonet S., Shah H.N., Cherkaoui A., Schrenzel J. Application and use of various mass spectrometry methods in clinical microbiology. Clin Microbiol Infect 2010, 16:1604-1613.
36. Peters R.P., van Agtmael M.A., Danner S.A., Savelkoul P.H., Vandenbroucke-Grauls C.M. New developments in the diagnosis of bloodstream infections. Lancet Infect Dis 2004, 4:751-760.
37. Maquelin K., Kirschner C., Choo-Smith L.P., Ngo-Thi N.A., van Vreeswijk T., Stammler M., et al. Prospective study of the performance of vibrational spectroscopies for rapid identification of bacterial and fungal pathogens recovered from blood cultures. J Clin Microbiol 2003, 41:324-329.
38. Bizzini A., Greub G. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, a revolution in clinical microbial identification. Clin Microbiol Infect 2010, 16:1614-1619.
39. Drancourt M. Detection of microorganisms in blood specimens using matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a review. Clin Microbiol Infect 2010, 16:1620-1625.
40. Yanagihara K., Kitagawa Y., Tomonaga M., Tsukasaki K., Kohno S., Seki M., et al. Evaluation of pathogen detection from clinical samples by real-time polymerase chain reaction using a sepsis pathogen DNA detection kit. Crit Care 2010, 14:R159.
41. Schrenzel J. PCR for the diagnosis of sepsis: hope or hype?. Crit Care 2011, 15:111.
42. Tang Y.W., Kilic A., Yang Q., McAllister S.K., Li H., Miller R.S., et al. StaphPlex system for rapid and simultaneous identification of antibiotic resistance determinants and Panton-Valentine leukocidin detection of staphylococci from positive blood cultures. J Clin Microbiol 2007, 45:1867-1873.
43. Bauer K.A., West J.E., Balada-Llasat J.M., Pancholi P., Stevenson K.B., Goff D.A. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010, 51:1074-1080.
44. Bravo D., Blanquer J., Tormo M., Aguilar G., Borras R., Solano C., et al. Diagnostic accuracy and potential clinical value of the LightCycler SeptiFast assay in the management of bloodstream infections occurring in neutropenic and critically ill patients. Int J Infect Dis 2011.
45. Chuang Y.C., Chang S.C., Wang W.K. High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy. PLoS One 2010, 5:e14133.
46. van der Poll T. Opal SM Host-pathogen interactions in sepsis. Lancet Infect Dis 2008, 8:32-43.
47. Nascimento D.C., Alves-Filho J.C., Sonego F., Fukada S.Y., Pereira M.S., Benjamim C., et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit Care Med 2010, 38:1718-1725.
48. Limaye A.P., Kirby K.A., Rubenfeld G.D., Leisenring W.M., Bulger E.M., Neff M.J., et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. Jama 2008, 300:413-422.
49. Heininger A., Haeberle H.A., Fischer I., Beck R., Riessen R., Rohde F., et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care 2011, 15:R77.
50. Tang B.M., Huang S.J., McLean A.S. Genome-wide transcription profiling of human sepsis: a systematic review. Crit Care 2010, 14:R237.
51. Delano M.J., Thayer T., Gabrilovich S., Kelly-Scumpia K.M., Winfield R.D., Scumpia P.O., et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J Immunol 2011, 186:195-202.
52. Souto F.O., Alves-Filho J.C., Turato W.M., Auxiliadora-Martins M., Basile-Filho A., Cunha F.Q. Essential role of CCR2 in neutrophil tissue infiltration and multiple organ dysfunction in sepsis. Am J Respir Crit Care Med 2011, 183:234-242.
53. Alves-Filho J.C., de Freitas A., Spiller F., Souto F.O., Cunha F.Q. The role of neutrophils in severe sepsis. Shock 2008, 30(Suppl. 1):3-9.
54. Niessen F., Schaffner F., Furlan-Freguia C., Pawlinski R., Bhattacharjee G., Chun J., et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 2008, 452:654-658.
55. Ruf W., Furlan-Freguia C., Niessen F. Vascular and dendritic cell coagulation signaling in sepsis progression. J Thromb Haemost 2009, 7(Suppl 1):118-121.
56. Landelle C., Lepape A., Voirin N., Tognet E., Venet F., Bohe J., et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 2010, 36:1859-1866.
57. Lawrence K.L., White P.H., Morris G.P., Jennemann J., Phelan D.L., Hotchkiss R.S., et al. CD4+ lymphocyte adenosine triphosphate determination in sepsis: a cohort study. Crit Care 2010, 14:R110.
58. Lukaszewicz A.C., Grienay M., Resche-Rigon M., Pirracchio R., Faivre V., Boval B., et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009, 37:2746-2752.
59. Monneret G., Venet F., Pachot A., Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14:64-78.
60. Oiva J., Mustonen H., Kylänpää M.L., Kyhäla L., Kuuliala K., Siitonen S., et al. Acute pancreatitis with organ dysfunction associates with abnormal blood lymphocyte signaling: controlled laboratory study. Crit Care 2010, 14:R207.
61. Caldwell C.C., Hotchkiss R.S. The first step in utilizing immune-modulating therapies: immune status determination. Crit Care 2011, 15:108.
62. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
63. Swarup V., Rajeswari M.R. Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007, 581:795-799.
64. Saukkonen K., Lakkisto P., Pettila V., Varpula M., Karlsson S., Ruokonen E., et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin Chem 2008, 54:1000-1007.
65. Zeerleder S., Zwart B., Wuillemin W.A., Aarden L.A., Groeneveld A.B., Caliezi C., et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003, 31:1947-1951.
66. Huttunen R., Kuparinen T., Jylhävä J., Aittoniemi J., Vuento R., Huhtala H., et al. Fatal outcome in bacteremia is characterized by high plasma cell free DNA concentration and apoptotic DNA fragmentation: a prospective cohort study. PLoS One 2011, 6:e21700.
67. Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003, 197:263-268.
68. Sweet M.J., Leung B.P., Kang D., Sogaard M., Schulz K., Trajkovic V., et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001, 166:6633-6639.
69. Barochia A., Solomon S., Cui X., Natanson C., Eichacker P.Q. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 2011, 7:479-494.
70. Tidswell M., Tillis W., Larosa S.P., Lynn M., Wittek A.E., Kao R., et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010, 38:72-83.
71. Haziot A., Rong G.W., Lin X.Y., Silver J., Goyert S.M. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995, 154:6529-6532.
72. Reinhart K., Gluck T., Ligtenberg J., Tschaikowsky K., Bruining A., Bakker J., et al. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 2004, 32:1100-1108.
73. Chatterjee A., Snead C., Yetik-Anacak G., Antonova G., Zeng J., Catravas J.D. Heat shock protein 90 inhibitors attenuate LPS-induced endothelial hyperpermeability. Am J Physiol Lung Cell Mol Physiol 2008, 294:L755-L763.
74. Brahmamdam P., Inoue S., Unsinger J., Chang K.C., McDunn J.E., Hotchkiss R.S. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010, 88:233-240.
75. Zhang Y., Zhou Y., Lou J., Li J., Bo L., Zhu K., et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010, 14:R220.
76. Inoue S., Bo L., Bian J., Unsinger J., Chang K., Hotchkiss R.S. Dose Dependent Effect of Anti-CTLA-4 on Survival in Sepsis. Shock 2011.
77. Shui J.W., Steinberg M.W., Kronenberg M. Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J Leukoc Biol 2011, 89:517-523.
78. Kreymann K.G., de Heer G., Nierhaus A., Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007, 35:2677-2685.
79. Meisel C., Schefold J.C., Pschowski R., Baumann T., Hetzger K., Gregor J., et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648.
80. Bo L., Wang F., Zhu J., Li J., Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011, 15:R58.
81. Nakamura T., Kawagoe Y., Matsuda T., Koide H. Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med 2004, 30:1838-1841.
82. Nakamura T., Ebihara I., Shoji H., Ushiyama C., Suzuki S., Koide H. Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm Res 1999, 48:171-175.
83. Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Lerma F.A., et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005, 23:400-405.
84. Novelli G., Ferretti G., Poli L., Pretagostini R., Ruberto F., Perrella S.M., et al. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion. Transplant Proc 2010, 42:1021-1024.
85. Davies B., Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 2011, 11:65-71.
86. Cruz D.N., Perazella M.A., Bellomo R., de Cal M., Polanco N., Corradi V., et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007, 11:R47.
87. Cruz D.N., Antonelli M., Fumagalli R., Foltran F., Brienza N., Donati A., et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. Jama 2009, 301:2445-2452.
88. Totsugawa T., Kuinose M., Yoshitaka H., Tsushima Y., Ishida A., Chikazawa G., et al. Intraoperative direct hemoperfusion with a polymyxin-B immobilized fiber column for treatment of infective endocarditis. Gen Thorac Cardiovasc Surg 2011, 59:98-104.
89. Gutsmann T., Razquin-Olazaran I., Kowalski I., Kaconis Y., Howe J., Bartels R., et al. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob Agents Chemother 2010, 54:3817-3824.
90. Manzoni P., Rinaldi M., Cattani S., Pugni L., Romeo M., Messner H., et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weihgt neonates: a randomized trial. JAMA 2009, 302:1421-1428.
91. Mohan P., Abrams S. Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2009, CD007138.
92. Venkatesh M., Abrams S. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2010, CD00137.
93. Cauwels A. Nitric oxide in shock. Kidney Int 2007, 72:557-565.
94. Lopez A., Lorente J.A., Steingrub J., Bakker J., McLuckie A., Willatts S., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004, 32:21-30.
95. Cauwels A., Brouckaert P. Nitrite regulation of shock. Cardiovasc Res 2011, 89:553-559.
96. Cauwels A., Buys E.S., Thoonen R., Geary L., Delanghe J., Shiva S., et al. Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase-dependent manner. J Exp Med 2009, 206:2915-2924.
97. Annane D., Bellissant E., Bollaert P.E., Briegel J., Confalonieri M., De Gaudio R., et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. Jama 2009, 301:2362-2375.
98. Sprung C.L., Annane D., Keh D., Moreno R., Singer M., Freivogel K., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124.
99. Minneci P.C., Deans K.J., Banks S.M., Eichacker P.Q., Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004, 141:47-56.
100. Annane D., Sebille V., Charpentier C., Bollaert P.E., Francois B., Korach J.M., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Jama 2002, 288:862-871.
101. Patel G.P., Balk R.A. Systemic Steroids in Severe Sepsis and Septic Shock. Am J Respir Crit Care Med 2011.
102. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
103. Bernard G.R., Macias W.L., Joyce D.E., Williams M.D., Bailey J., Vincent J.L. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003, 7:155-163.
104. Abraham E., Laterre P.F., Garg R., Levy H., Talwar D., Trzaskoma B.L., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341.
105. Eichacker P.Q., Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007, 33:396-399.
106. Norrby-Teglund A., Haque K.N., Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 2006, 260:509-516.
107. Kasten K.R., Prakash P.S., Unsinger J., Goetzman H.S., England L.G., Cave C.M., et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun 2010, 78:4714-4722.
108. Inoue S., Unsinger J., Davis C.G., Muenzer J.T., Ferguson T.A., Chang K., et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010, 184:1401-1409.
109. Unsinger J., McGlynn M., Kasten K.R., Hoekzema A.S., Watanabe E., Muenzer J.T., et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 2010, 184:3768-3779.
110. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71.
111. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365:756-759.
112. Emonts M., Sweep F.C., Grebenchtchikov N., Geurts-Moespot A., Knaup M., Chanson A.L., et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007, 44:1321-1328.
113. Tleyjeh I.M., Kashour T., Hakim F.A., Zimmerman V.A., Erwin P.J., Sutton A.J., et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169:1658-1667.
114. Novack V., Eisinger M., Frenkel A., Terblanche M., Adhikari N.K., Douvdevani A., et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009, 35:1255-1260.
115. Janda S., Young A., Fitzgerald J.M., Etminan M., Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010, 25. 656 e7-22.
116. Yende S., Milbrandt E.B., Kellum J.A., Kong L., Delude R.L., Weissfeld L.A., et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011, 39(1).
117. Kruger P.S., Harward M.L., Jones M.A., Joyce C.J., Kostner K.M., Roberts M.S., et al. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011, 183:774-781.
118. Simvastatin and severe sepsis: A randomised controlled Trial (SimSepT) Available at:, Accessed July 13. http://www.controlled-trials.com/ISRCTN92093279/.
119. Statins for the Early Treatment of Sepsis (SETS) Available at:, Accessed July 13. http://www.controlled-trials.com/show/NCT00528580.
120. Arcaroli J., Fessler M.B., Abraham E. Genetic polymorphisms and sepsis. Shock 2005, 24:300-312.
121. Brouwer M.C., de Gans J., Heckenberg S.G., Zwinderman A.H., van der Poll T., van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:31-44.
122. Sutherland A.M., Walley K.R. Bench-to-bedside review: Association of genetic variation with sepsis. Crit Care 2009, 13:210.
123. Wong H.R., Shanley T.P., Sakthivel B., Cvijanovich N., Lin R., Allen G.L., et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics 2007, 30:146-155.
124. Wong H.R., Cvijanovich N., Lin R., Allen G.L., Thomas N.J., Willson D.F., et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 2009, 7:34.
125. Wong H.R., Wheeler D.S., Tegtmeyer K., Poynter S.E., Kaplan J.M., Chima R.S., et al. Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept. Crit Care Med 2010, 38:1955-1961.
126. Yende S., Kellum J.A. Understanding genetics of sepsis: will new technology help?. Crit Care 2009, 13:141.
127. Carson W.F., Cavassani K.A., Dou Y., Kunkel S.L. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 2011, 6:273-283.
128. Cornell TT, Wynn J, Shanley TP, Wheeler DS, Wong HR. Mechanisms and regulation of the gene-expression response to sepsis. Pediatrics 210;125: 1248-1258.
129. Baudouin S.V., Saunders D., Tiangyou W., Elson J.L., Poynter J., Pyle A., et al. Mitochondrial DNA and survival after sepsis: a prospective study. Lancet 2005, 366:2118-2121.
130. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
131. Rao P., Hayden M.S., Long M., Scott M.L., West A.P., Zhang D., et al. IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature 2010, 466:1115-1119.
132. Knoell D.L., Julian M.W., Bao S., Besecker B., Macre J.E., Leikauf G.D., et al. Zinc deficiency increases organ damage and mortality in a murine model of polymicrobial sepsis. Crit Care Med 2009, 37:1380-1388.
133. Bao S., Liu M.J., Lee B., Besecker B., Lai J.P., Guttridge D.C., et al. Zinc modulates the innate immune response in vivo to polymicrobial sepsis through regulation of NF-kappaB. Am J Physiol Lung Cell Mol Physiol 2010, 298:L744-L754.
134. Huttunen R., Syrjänen J., Aittoniemi J., Oja S.S., Raitala A., Laine J., et al. High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 2010, 33:149-154.
135. Tattevin P., Monnier D., Tribut O., Dulong J., Bescher N., Mourcin F., et al. Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis 2010, 201:956-966.
136. Wang Y., Liu H., McKenzie G., Witting P.K., Stasch J.P., Hahn M., et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 2010, 16:279-285.
137. Pellegrin K., Neurauter G., Wirleitner B., Fleming A.W., Peterson V.M., Fuchs D. Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma. Shock 2005, 23:209-215.
138. Darcy C.J., Davis J.S., Woodberry T., McNeil Y.R., Stephens D.P., Yeo T.W., et al. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. PLoS One 2011, 6:e21185.
139. Schefold J.C., Zeden J.P., Pschowski R., Hammoud B., Fotopoulou C., Hasper D., et al. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scand J Infect Dis 2009.
140. Riedemann N.C., Guo R.F., Ward P.A. Novel strategies for the treatment of sepsis. Nat Med 2003, 9:517-524.
141. Lyytikäinen O., Klemets P., Ruutu P., Kaijalainen T., Rantala M., Ollgren J., et al. Defining the population-based burden of nosocomial pneumococcal bacteremia. Arch Intern Med 2007, 167:1635-1640.
142. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787.
143. Matthews R.C., Rigg G., Hodgetts S., Carter T., Chapman C., Gregory C., et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003, 47:2208-2216.
144. Pachl J., Svoboda P., Jacobs F., Vandewoude K., van der Hoven B., Spronk P., et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404-1413.